Free radical pathology in schizophrenia: A review

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 55, Issue 1-2, 1996, Pages 33-43

  Reddy, Ravinder D ^a   Yao, Jeffrey K ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATALASE; FREE RADICAL; GLUTATHIONE PEROXIDASE; SUPEROXIDE DISMUTASE;

CONFERENCE PAPER; HUMAN; LIPID PEROXIDATION; MEMBRANE FLUIDITY; NERVE CELL MEMBRANE; PRIORITY JOURNAL; SCHIZOPHRENIA;

EID: 0029784312     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-3278(96)90143-X     Document Type: Conference Paper

References (137)

1. Halliwell B., Gutteridge J. M. C. Free radicals in biology and medicine. 2nd edn. Oxford; Clarendon Press, 1989.
2. Halliwell B. Reactive oxygen species and the central nervous system. J Neurochem 1992; 59: 1609-1623.
3. Lohr J. B. Oxygen radicals and neuropsychiatric illness: Some speculations. Arch Gen Psychiatr 1991; 48: 1097-1106.
4. van Kammen D., Yao J. G., Goetz K. Polyunsaturated fatty acids, prostaglandins, and schizophrenia. Ann NY Acad Sci 1989; 559: 411-423.
5. Horrobin D. F., Glen A. I. M., Vaddadi K. The membrane hypothesis of schizophrenia. Schizophr Res 1994; 13: 195-207
6. Cohen G. Enzymatic/nonenzymatic sources of oxyradicals and regulation of antioxidant defences. Ann NY Acad Sci 1994; 738: 8-14.
7. Kalyanaraman B. Free radicals from catecholamine hormones, neuromelanins, and neurotoxins. In: Miquel J., Quintanilha A. T., Weber H., eds. Handbook of Free Radicals and Antioxidants in Biomedicine. Vol I. Boca Raton: CRC Press, 1989; pp 147-159.
8. Rice-Evans C. A. Formation of free radicals and mechanisms of action in normal biochemical processes and pathological states. In: Rice-Evans C. A., Burdon R. H., eds. Free Radical Damage and its Control. Amsterdam: Elsevier 1994; pp 131-153.
9. Ernster L. Lipid peroxidation in biological membranes: Mechanisms and implications. In: Yagi K., ed. Active Oxygens, Lipid Peroxides, and Antioxidants. Japan: CRC Press, 1993; pp 1-38.
10. Horrobin D. F., Manku M. S., Morse-Fisher N. et al. Fatty acid levels in the brains of schizophrenics and normal controls. Biol Psychiatr1991; 30: 795-805.
11. Deby C., Deby-Dupont G. Oxygen species in prostaglandin biosynthesis in vitro and in vivo. In: Bannister W. H., Bannister J. V., eds. Development in Biochemistry Vol 1 1B: Biological and Clinical Aspects of Superoxide and Superoxide Dismutase. New York: Elsevier, 1980; pp 84-97.
12. Oliveira C. R., Agostinho P., Caseiro P., Duarte C. B., Caralho A. P. Reactive oxygen species and GABA release. Ann NY Acad Sci 1994; 738: 130-140.
13. Rafalowska U., Liu G-J., Floyd R. A. Peroxidation induced changes in synaptosomal transport of dopamine and g-aminobutyric acid. Free Radical Biol Med 1989; 6: 485-492.
14. Schwartz R. D., Skolnick P., Paul S. M. Regulation of gamma-aminobutyric acid/barbiturate receptor-gated chloride ion flux in brain vesicles by phospholipase A2: possible role of oxygen radicals. J Neurochem 1988; 50: 565-571.
15. Pellmar T. Electrophysiological correlates of peroxide damage in guinea pig hippocampus in vitro. Br Res 1986; 364: 377-381.
16. Levin E. Y., Kaufman S. J Biol Chem 1961; 236: 2043-2048.
17. Bartosz G. Commentary on: Free radicals and the developmental pathology of schizophrenic burnout. Integr Psychiatrt 1987; 5: 43-44.
18. Stevens J. D. The distribution of the phospholipid fractions in the red cell membrane of schizophrenics. Schizophr Bull 1972; 6: 60-61.
19. Rotrosen J., Wolkin A. Phospholipid and prostraglandin hypotheses of schizophrenia. In: Meltzer H. Y., ed. Psychopharmacology: The Third Generation of Progress. New York: Raven, 1987; pp 759-764.
20. Glen A. I. M., Glen E. M. T., Horrobin D. F. et al. A red cell membrane abnormality in a subgroup of schizophrenic patients. Evidence for two diseases. Schizophr Res 1994; 12: 53-61.
21. Yao J. K., van Kammen D. P., Gurlis J. Red blood cell membrane dynamics in schizophrenia. II. Fatty acid composition. Schizophr Res 1994; 13: 217-226.
22. Yao J. K., van Kammen D. P., Gurlis J. Red blood cell membrane dynamics in schizophrenia. III. Correlation of fatty acid abnormalities with clinical measures. Schizophr Res 1994; 13: 227-232.
23. Vaddadi K. S., Courtney P., Gilleard C. S., Manku M. S., Horrobin D. F. A double blind trial of essential fatty acid supplementation in patients with tardive dyskinesia. Psychiatr Res 1989; 27: 313-323.
24. Peet M., Laugharne J. D. E., Horrobin D. F., Reynolds G. P. Arachidonic acid: A common link in the biology of schizophrenia. Arch Gen Psychiatr 1994; 51: 665-666.
25. Lieberman J. A., Koreen A. R. Neurochemistry and neuroendocrinology of schizophrenia: A selective review. Schizophr Bull 1993; 19: 371-429.
26. Bourguignon A. Trial of evening primrose oil in the treatment of schizophrenia. L'Encephaale 1984; 10: 241-250.
27. Soulirac A., Lambinet H., Neuman J. C. Schizophrenia and Pgs: Therapeutic effects of PG precursors in the form of evening primrose oil. Ann Med Psychol 1983; 8: 888-890.
28. Vaddadi K. S., Courtney P., Gillard C. J., Manku M. S., Horrobin D. F. A double-blind trial of essential fatty acid supplementation in patients with tardive dyskinesia. Psychiat Res 1989; 27: 313-323.
29. Vaddadi K. S. Use of gamma-linolenic acid and in the treatment of schizophrenia and tardin dyskinesia. Prostaglandins Leukot Essent Fatty Acid 1992; 46: 67-70.
30. Heron D., Shinitzky M., Hershkowitz M., Samuel D. Lipid fluidity markedly modulates the bindings of serotonin to mouse brain membrane. Proc Natl Acad Sci USA 1980; 77: 7463-7467
31. Hirata F., Axelrod J. Phospholipid methylation and biological signal transmission. Science 1980; 209: 1082-1090.
32. Heron D., Hershkowitz M., Shinitzky M., Samuel D. The lipid fluidity of synaptic membranes and the binding of serotonin and opiate ligands. In: Littauer U. Z., Dudai Y., Silman I., Teichberg V. I1., Vogel Z., eds Neurotransmitters and their Receptors. John Wiley, 1980; pp 125-138.
33. Davidson B., Cantrill R. C., Kurstjens N. P. et al. Essential fatty acid deprivation of cats reduced the activity of apomorphine at presynaptic dopamine receptors modulating dopamine release from caudate slices. Eur J Pharmacol
34. Hitzeman R. J., Hirschowitz J., Garver D. I. On the physical properties of red cell ghost membranes in the affective disorders and psychoses, a fluorescence polarization study. J Affect Disord 1986; 10: 227-232.
35. Pettegrew J. W., Keshavan M. S., Panchalingam K. et al. Alterations in brain high energy phosphate and membrane phospholipid metabolism in first episode drug naive schizophrenics. Arch Gen Psychiatr 1991; 48: 563-568.
36. Yao et al.
37. 31P hosphorus MRSI in the frontal and parietal lobes in schizophrenia. Biol Psychiatr 1993; 33: 46A.
38. 31P magnetic resonance spectroscopy of schizophrenic patients with neuroleptic resistant positive and negative symptoms. Biol Psychiatr 1992; 31(S): 204A-205A.
39. 1H MRS. Schizopkr Res 1993; 9: 210.
40. Williamsion P., Drost D., Stanley J, Carr T. et al. Localized phosphorus 31 magnetic resonance spectro-scopy in chronic schizophrenic patients and normal controls. [Letter] Arch Gen Psychiatr 1991; 48: 578.
41. Suddath R. L., Casanova M. F., Goldberg T. E., Daniel D. G., Kelsoe, J. R. Jr., Weinbergerl D. R. Temporal lobe pathology in schizophrenia: A quanititative magnetic resonance imaging study. Am J Psychiatr 1989; 146: 464-472.
42. Rossi A., Sratta P., D'Albenzio L., Tartaro A., Schizaaz G., deMichele V., Bolino F., Casacchia M. Reduced temporal lobe areas in schizophrenia: Preliminary evidences from a controlled muliplanar magnetic resonance imaging study. Biol Psychiatr 1990; 27: 611-668.
43. Herman K. F., Weinberger D. R. Functional localisation in the brain in schizophrenia. In: Talisman A., Goldfinger, S. M., eds. American Psychiatric Press Review of Psychiatry 1991; 10: 24-59.
44. Shenton M. E., Kikinis R., Jolesz R. A. et al. Left-lateralized temporal lobe abnormalities and their relationship to thought disorder: A computerized, quantitative MRI study. N Engl J Med 1992; 327: 604-612.
45. Keshavan M. S., Pettegrew J. W., Ward R. Are membrane phospholipid changes in schizophrenia familial? Biol Psychiatr 1993; 33: 37A-162A.
46. Hoffer A., Osmand H., Smythies J. Schizophrenia: new approach. J Ment Sci 1954; 100: 29-45.
47. Abdalla D. S. P., Manteiro H. P., Olivera J. A. C., Bechara C. H. Activities of superoxide dismutase and glutathione peroxidase in schizophrenic and manic depressive patients. Clin Chem 1986; 32: 805-807.
48. Golse B., Debray-Ritzen P., Puget K., Michelson A. M. Dosages erythrocytaires et plaquettes des superoxyde dismutases (1 et 2) et de la glutathion peroxydase dans les pychoses infantiles de développement. Nouv Pr Med 1978; 7: 1952.
49. Golse B., Debray Q., Puget K., Michelson A. M. Dosages érythrocytaires de la superoxyde dismutases 1 et de la glutathion peroxydase dans les schizophrénies de l'adulte. Nouv Pr Med 1978; 7: 2070-2071.
50. Michelson A. M., Puget K, Durosay P., Bouneau J. C. Clinical aspects of the dosage of erythrocuprein. In: Michelson A. M., McCord J. M., Fridovich I., eds. Superoxide and Superoxide Dismutase London: Academic Press, 1977; pp 467-499.
51. Reddy R., Mahadik S. P., Mukherjee M., Murthy J. N. Enzymes of the antioxidant system in chronic schizophrenic patients. Biol Psychiatr 1991; 30: 409-412.
52. Wang H. An investigation on changes in blood CuZn-superoxide dismutase contents in type I, II schizophrenics. Chung Hua Shen Ching Ching Shen Ko Tsa Chih 1992; 25: 6-8.
53. Vaiva G., Thomas P., Leroux J. M. et al. Erythrocyte superoxide dismutase (eSOD) determination in positive moments of psychosis. Therapie 1994; 49: 343-348.
54. Sinet P. M., Debray Q., Carmagnol F., Pelicier Y., Nicole A., Jerome H. Normal erythrocyte SOD values in two human diseases: Schizophrenia and cystic fibrosis. In: Greenwald R. A., Cohen G., eds. Oxy Radicals and their Scavenger Systems. Vol. II. Cellular and Medical Aspects. New York: Elsevier, 1983; pp 302-304.
55. Mukherjee S., Mahadik S. P., Correnti E. E., Scheffer R. The antioxidant defense system at the onset of psychosis. Biol Psychiatr 1994; 35: 701.
56. Stoklasova A., Zapletalek M., Kudrnova K., Randova Z. Glutathione peroxidase activity of blood in chronic schizophrenics. Sbu Ved Praci Lek Fak UK v Hradci Kralove 1986; (Suppl.) 29 (1-2): 103-108.
57. Golse B., Debray-Ritzen P., Puget K., Michelson A. M. Dosages de la superoxyde dismutases 1 plaquettaire dans les pychoses infantiles de développement. Nouv Pr Med 1977; 6: 2449.
58. Glazov A., Mamzev V. P. Catalase in the blood and leucocytes in patients with nuclear schizophrenia. Zh Nevropatol Psikhlatr 1976; 4: 549-552.
59. Reddy R., Kelkar H., Mahadik S. P., Mukherjee S. Abnormal erythrocyte catalase activity in schizophrenic patients. Schizophr Res 1993; 9: 227.
60. Sohal R. S., Orr W. C. Relationship between antioxidants, prooxidants, and the aging process. Ann NY Acad Sci 1992; 663: 74-84.
61. Guliaeva N. V., Levshina I. P., Obidin A. M. Indices of lipid free-radical oxidation and the antiradical protection of the brain - the neurochemical correlates of the development of the general adaptation syndrome. Zh Vyssh Nerv Deiat 1988; 38: 731-737.
62. Prilipko L. L. Activation of lipid peroxidation under stress and in schizophrenia. In: Kemali D., Morozov P. V., Toffano G., eds. New Research Strategies in Biological Psychiatry. Biological Psychiatry-New Perspectives: 3. London: John Libbey, 1984.
63. Prilipko L. L. The possible role of lipid peroxidation in the pathophysiology of mental disorders. In: Packer L., Prilipko L., Christen Y., eds. Free Radicals in the Brain. Berlin: Spinger-Verlag, 1992; pp 146-152.
64. Sram R. J., Binkova B. Side-effects of psychotropic therapy. In: Packer L., Prilipko L., Christen Y., eds. Free Radicals in the Brain. Berlin: Spinger-Verlag, 1992; pp 153-166.
65. Scheffer R., Diamond B. I., Correnti E. E., Borison R. L., Mahadik S. P., Mukherjee S. Plasma lipid peroxidation and HVA in first episode psychosis. Biol Psychiatr 1995; 37: 681.
66. Kovaleva E. S., Orlov O. N., Tsutsul'kovskia M. I. A., Vladimirova T. V., Beliaev T. S. Lipid peroxidation processes in patients with schizophrenia. Zh Nevropatol Psikiatr 1989; 89: 108-110.
67. Phillips M., Sabas M., Greenberg J. Increased pentane and carbon disulfide in the breath of patients with schizophrenia. J Clin Pathol 1993; 46: 861-864.
68. Wise C. D., Baden M. M., Stein L. Post-mortem measurement of enzymes in human brain: evidence of a central noradrenergic deficit in schizophrenia. J Psychiatr Res 1974; 11: 185-198.
69. Miyakawa T., Sumiyoshi S., Deshimaru M. Electron microscopic study on schizophrenia. Mechanism of pathological changes. Acta Neuropathologist (Berlin) 1972; 20: 67-77.
70. Averback P. Structural lesions of the brain of young schizophrenics. Can J Neurol Sci 1981; 8: 73-76.
71. Senitz D., Winkelmann E. Über morphologische Befunde in der orbitofrontalen Rinde bei Menschen mit schizophrenen Psychosen. Eine Golgi- und eine elektonenoptische Studie. Psychiatrie, Neurologie und medizinische Psychologie 1981; 33: 1-9.
72. Roberts G. W. Schizophrenia: A neuropathological perspective. Br J Psychiatr 1991; 158: 8-17.
73. Topinka J., Binkova B., Sram R. J. DNA repair synthesis and lipid peroxidation in schizophrenic patients. Schizophr Res 1988; 1: 520.
74. Suboticanec K., Folnegovic-Smalc V., Korbar M., Mestrovic B., Buzina R. Vitamin C status in chronic schizophrenia. Biol Psychiatr 1990; 28: 959-966.
75. Buckman T. D., Kling A. S., Eiduson S., Sutphin M. S., Steinberg A. Glutathione peroxidase and CT scan abnormalities in schizophrenia. Biol Psychiatr 1987; 22: 349-356.
76. Buckman T. D., Kling A. S., Eiduson S., Sutphin M. S., Steinberg A., Eiduson S. Platelet glutathione peroxidase and monoamine oxidase activity in schizophrenics with CT scan abnormalities: Relation to psychosocial variables. Psychiatr Res 1990; 31: 1-14.
77. Reddy R., Kelkar H., Mahadik S. P., Mukherjee S. Free radicals and neurological signs in chronic schizophrenic patients. Biol Psychiatr 1994; 35: 699-700.
78. Scheffer R., Diamond B. I., Correnti E. E., Borison R. L., Mahadik S. P., Mukherjee S. Plasma lipid peroxidation and HVA in first episode psychosis. Biol Psychiatr 1995; 37: 681.
79. Scheffer R., Mahadik S. P., Correnti E. E., McClure M., Mukherjee S. Membrane lipid peroxidation and neurological signs in first episode psychosis. Biol Psychiatr 1995; 37: 681.
80. Murthy J. N., Laev H., Karpiak S., Mahadik S. P. Enzymes of oxyradical metabolism after haloperidol treatment of rat. Soc Neurosci 1989; 15: 139.
81. Roy D., Pathak D. N., Singh R. Effects of chlorpromazine on the activities of antioxidant enzymes and lipid peroxidation in various regions of aging rat brain. J Neurochem 1984; 42: 268-633.
82. Szabo L., Lajko K., Barabas K., Matkovics B. Effects of neuroleptics on lipid peroxidation and peroxide metabolism enzyme activities in various discrete areas of the rat brain. Chem Pharmacol 1983; 14: 537-539.
83. Lohr J. B., Kuczenski R., Bracha H. S., Moir M., Jeste D. V. Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia. Biol Psychiatr 1990; 28: 535-539.
84. Pall H. S., Williams A. C., Blake D. R., Lunec J. Evidence of enhanced lipid peroxidation in the cerebrospinal fluid of patients taking phenothiazines. Lancet 1987; ii: 596-599.
85. Sram R. J., Binkova B., Koclsova J. et al. Antioxidant effects on alcohol, drugs, and aging. In: Medelsohn M. L., Albertini R. J., eds. Mutation and The Environment. New York: Wiley-Liss, 1990; pp 327-337
86. Reddy R., Mahadik S. P., Mukherjee S., Makar T. Neuroleptic effects on the enzymes of the antioxidant defense system in manic and schizophrenic patients. Biol Psychiatr 1992; 31: 248.
87. Linday L. A., Pippenger C. E., Howard A., Lieberman J. A. Free radicals scavenging enzyme activity and related trace metals in clozapine-induced agranulocytosis: A pilot study. J Clin Psychopharmacol 1995; 16: 353-359.
88. Kane J., Lieberman J., Woerner M., Borenstein M., Alvir J Tardive dyskinesia: New Research. In: Schulz S. C., Tamminga C. A., eds. Schizophrenia: Scientific Progress. New York: Oxford University Press, 1989; pp 381-386.
89. Crow T. J., Cross A. J., Johnstone E. C., Owen F., Owens D. G. C., Waddington J. L. Abnormal involuntary movements in schizophrenia: Are they related to the disease process or its treatment? Are they associated with changes in the dopamine receptors? J Clin Psychopharm 1982; 2: 336-340.
90. Cadet J. L., Lohr J. B., Jeste D. V. Free radicals and tardive dyskinesia. TINS 1986; 9: 107-108.
91. Cadet J. L., Lohr J. B. Free radicals and the developmental pathology of schizophrenic burnout. Integr Psychiatr 1987; 5: 40-48.
92. Cadet J. L., Lohr J. B. Possible involvement of free radicals in neuroleptic-induced movement disorders. Evidence from treatment of tardive dyskinesia with vitamin E. Ann NY Acad Sci 1989; 570: 176-185.
93. Tsai G., Goff D., Coyle J. T. Oxidative stress and gluamatergic hypothesis of tardive dyskinesia. Neurosci Abstr 1994; 20: 671.
94. Peet M., Laugharne J., Rangarajan N., Reynolds G. P. Tardive dyskinesia, lipid peroxidation, and sustained amelioration with vitamin E treatment. Int Clin Psychopharmacol 1993; 8: 151-135.
95. Zubenko G. S., Cohen B. M. A cell membrane correlate of tardive dyskinesia in patients treated with phenothiazines. Psychopharmacology 1986; 88: 230-236.
96. Beuttner G. R. The pecking order of free radicals and antioxidants: lipid peroxidation, alpha-tocopherol, and ascorbate. Arch Biochem Biophys 1993; 300: 535-543.
97. Burton G. W., Ingold K. U. Vitamin E as an in vitro and in vivo oxidant. Ann NY Acad Sci 1989; 570: 7-22.
98. Adler L. A., Peselow E., Rotrosen J., Duncan E., Lee M., Rosenthal M., Rotrosen J. Vitamin E in tardive dyskinesia: Effects of longer term treatment. Am Coll Neuropsychopharmacol 31st Annual Meeting 1992; Poster session III: 213.
99. Adler L. A., Peselow E., Rotrosen J., Duncan E., Lee M., Rosenthal M., Angrist B. Vitamin E treatment of tardive dyskinesia. Am J Psychiatr 1993; 150: 1405-1407
100. Dabiri L. M., Pasta D., Darby J. M., Mosbacher D. Effectiveness of vitamin E for treatment of long-term tardive dyskinesia. Am J Psychiatrt 1994; 151: 925-926.
101. Egan M. F., Hyde T. M., Albers G. W. et al. Treatment of tardive dyskinesia with vitamin E. Am J Psychiatr 1992; 149: 773-777.
102. Elkashef A. M., Ruskin P. E., Bacher N., Barrett D. Vitamin E in the treatment of tardive dyskinesia. Am J Psychiatr 1990; 147: 505-506.
103. Junker D., Steigleider P., Gattaz W. F. Alpha-tocopherol in the treatment of tardive dyskinesia. Clin Beuropharmacol 1992; 15(Suppl): 639B.
104. Lohr J. B., Cadet J. L., Lohr M. A., Jeste D. V., Wyatt R. J. Alpha-tocopherol in tardive dyskinesia. Lancet 1987; i: 913-914.
105. Lam L. C. W., Chiu H. F. K., Hung S. F. Vitamin E in the treatment of tardive dyskinesia: A replication study. J Nerv Ment Dis 1994; 182: 113-114.
106. Shriqui C. L., Bradwejn J., Annable L., Jones B.D. Vitamin E in the treatment of tardive dyskinesia: a double-blind placebo-controlled study. Am J Psychiatr 1992; 149: 391-393.
107. Sram R. J., Binkova B. Side-effects of psychotropic therapy. 1992
108. Sinet P. M. Metabolism of oxygen derivatives in Down's syndrome. Ann NY Acad Sci 1982; 396: 83-94.
109. Sinet P. M., Lejeune J., Jerome H. Trisomy 21 (Down's syndrome), glutathione peroxidase, hexose monophosphate shunt and I.Q. Life Sci 1979; 24: 29-34.
110. Percy M. E., Dalton A. J., Markovic V. D. et al. Red cell superoxide dismutase, glutathione peroxidase and catalase in Down's syndrome patients with and without manifestations of Alzheimer disease. Am J Med Genet 1990; 35: 459-467.
111. Anneren G., Gardner A., Lundin T. Increased glutathione peroxidase activity in erythrocytes in patients with Alzheimer's disease/senile dementia of Alzheimer's type. Acta Neurol Scand 1986; 73: 586-589.
112. Clausen J. Demential syndromes and the lipid metabolism. Acta Neurol Scand 1984; 70: 345-355.
113. Delacourte A., Defossez A., Ceballos I., Nicole I., Sinet P. M. Preferential localization of copper zinc superoxide dismutase in the vulnerable cortical neurons in Alzheimer's disease. Neurosci Lett 1988; 92: 247-253.
114. Richardson J. S. Free radicals in the genesis of Alzheimer's disease. Ann NY Acad Sci 1993; 695: 73-76.
115. Zelman F. P., Thienhaus O. J., Bosmann H. B. Superoxide dismutase activity in Alzheimer's disease: possible mechanism for paired helical filament formation. Br Res 1989; 476: 160-162.
116. Subbarao K. V., Richardson J. S., Ang L. C. Autopsy samples of Alzheimer's cortex show increased peroxidation in vitro. J Neurochem 1990; 55: 342-345.
117. Abdalla D. S. P., Manteiro H. P., Bechara C. H. Oxidative stress in brain caused by 6-hydroxydopamine. A model for schizophrenia. In: Hayaishi et al, eds. Medical, Biochemical and Chemical Aspects of Free Radicals. Amsterdam: Elsevier, 1989.
118. Guliaeva N. V., Levshina I. P., Obidin A. M. Indices of lipid free-radical oxidation and the antiradical protection of the brain - the neurochemical correlates of the development of the general adaptation syndrome. Zh Vyssh Nerv Deiat 1988; 38: 731-737.
119. Lohr J. B., Browning J. A. Free radical involvement in neuropsychiatric illnesses. Psychopharmacol Bull 1995; 31: 159-165.
120. Donaldson J. The physiopathologic significance of manganese in the brain: its relation to schizophrenia and neurodegenerative disorders. NeuroToxicology 1987; 8: 451-462.
121. Laplante M., Tran-Manh N. Etiology and pathogenesis of idiopathic parkinsonism: a model. Agressologie 1973; 14: 287-307.
122. Cohen G. The pathobiology of Parkinson's disease: biochemical aspects of dopamine neuron senescence. J Neural Transm (Suppl) 1983; 19: 89-103.
123. Ambani L. M., van Woert M. H., Murphy S. Brain peroxidase and catalase in Parkinson's disease. Arch Neurol 1975; 32: 114-118.
124. Larsen N. A., Pakkenberg H., Damsgaard E., Heydorn K., Wold S. Distribution of arsenic, manganese, and selenium in the human brain in chronic renal insufficiency, Parkinson's disease, and amyotrophic lateral sceloris. J Neurol Sci 1981; 51: 437-446.
125. Kish S. J., Morito C., Hornykiewicz O. Glutathione peroxidase activity in Parkinson's disease brain. Neurosci Lett 1985; 58: 343-346.
126. Marttila B. J., Lorentz H., Rinne U. K. Oxygen toxicity protecting enzymes in Parkinson's disease. Increase of superoxide dismutase-like activity in the substantia nigra and basal nucleus. J Neurol Sci 1988; 86: 321-331.
127. Saggu H., Cooksey J., Dexter D. et al. A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra. J Neurochem 1989; 53: 692-697.
128. Dexter D. T., Holley A. E., Flitter W. D. et al. Increased levels of lipid hydroperoxides in the Parkinsonian substantia nigra: An HPLC and ESR study. Movem Disor 1994; 9: 92-97.
129. Kopin I. J. Neurotoxins affecting biogenic aminergic neurons. In: Meltzer H. Y., ed. Psychopharmacology: The Third Generation of Progress. New York: Raven Press, 1987; pp 351-358.
130. Graham D. G. Commentary on: Free radicals and the developmental pathology of schizophrenic burnout. Integr Psychiatr 1987; 5: 44-45.
131. Floyd R. A. Role of oxygen free radicals in carcinogenesis and brain ischemia. FASEB J 1990; 2: 2587-2597.
132. Emerit J., Chaudiere J. Free radicals and lipid peroxidation in cell pathology. In: Miquel J., Quintanilha A., Weber H., eds. CRC Handbook of Free Radicals and Antioxidants in Biomedicine. Vol 1. Boca Raton: CRC Press, 1989; pp 177-185.
133. Capel I. D. Factors affecting antioxidant defense potential. In: Chow C. K., ed. Cellular Antioxidant Defense Mechanisms. Boca Raton: CRC Press, 1988; pp 191-215.
134. Marttila B. J., Roytta M., Lorentz H., Rinne U. K. Oxygen toxicity protecting enzymes in the human brain. J Neural Trans 1988; 74: 87-95.
135. Cohen G. Catalase, glutathione peroxidase, superoxide dismutase, and cytochrome P-450. In: Lajtha, ed. Handbook of Neurochemistry. 2nd edn. Vol 4. Enzymes in the nervous system. New York: Plenum Press, 1983; pp 315-330.
136. Shapiro R. M. Regional neuropathology in schizophrenia: Where are we? Where are we going? Schizophr Res 1993; 10: 187-239.
137. Reddy R. Is free radical pathology of any consequence in schizophrenia and its treatment. Biol Psychiatr 1994; 33: 700.